Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an agreement with the Abu Dhabi ...

Doctors in Dallas and other parts of Texas are beginning to use a new blood test that can detect colon cancer earlier. The ...

周二，BTIG将Guardant Health（纳斯达克股票代码：GH）的目标价从此前的50.00美元上调至55.00美元，同时维持对该股的买入评级。此次调整是在Guardant Health股价当天上午飙升15%之后做出的，原因是该公司宣布其Guardant Reveal ...

北京时间2025年02月01日03时00分，Guardant Health, Inc.（GH.us）股票出现异动，股价急速下挫5.07%。截至发稿，该股报47.41美元/股，成交量137.507万股， 换手率 1.11%，振幅4.67%。

to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant’s Shield™ test. The agreement was set up through Hikma Pharmaceuticals PLC, a multinational ...

GH's early success with SHIELD and future potential in multi-cancer detection is promising, but current risks outweigh potential returns, leading to my neutral view. Guardant Health is one of the ...

--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the National Cancer Institute (NCI) has selected the company’s Shield™ multi-cancer ...

Guardant Health (GH) announced an agreement with the Abu Dhabi Public Health Center ADPHC to introduce a non-invasive blood-based screening ...

Guardant Health (GH) announced the National Cancer Institute, or NCI, has selected the company’s Shield multi-cancer detection test for use in its Vanguard study, which will address the ...

The company’s blood test, Shield, is approved by the FDA for colorectal cancer (CRC) screening in adults aged 45 and older who are at average risk for the disease. According to Guardant Health ...